Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination immunization regimen using two types of poliovirus vaccines: - **Fractional Inactivated Poliovirus Vaccine (fIPV):** A reduced-dose (1/5th of the full dose) inactivated poliovirus vaccine administered intradermally. It induces immunity against all three types of polioviruses and is used to optimize limited IPV supply while maintaining high immunogenicity[8][7][1]. - **Bivalent Oral Polio Vaccine (bOPV):** An oral live attenuated vaccine that protects against poliovirus types 1 and 3 but not type 2[3][2]. The sequential schedule typically involves two doses of fIPV followed by two or three doses of bOPV during infancy. This approach provides robust protection against all wild-type polioviruses and supports global eradication efforts by maximizing immune response while conserving IPV supplies[1][3]. The mechanism of action for both components is induction of protective immunity via stimulation of humoral and mucosal immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inactivated poliovirus vaccine (fractional dose) + bivalent oral polio vaccine.